Volume 27, Issue 4 (7-2023)                   IBJ 2023, 27(4): 191-198 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hajihassan Z, Mohammadpour saray M, Yaseri A. Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor. IBJ 2023; 27 (4) :191-198
URL: http://ibj.pasteur.ac.ir/article-1-3874-en.html
Abstract:  
Background: T-cell immunoglobulin domain and mucin domain-3 (TIM-3) is an inhibitory receptor expressed in a variety of cells, including dendritic cells, T-helper 1 lymphocytes, and natural killer cells. Binding of this protein to its ligand, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), causes T-cell exhaustion, a specific condition in which effector T cells lose their ability to proliferate and produce cytokines. Blocking this inhibitory receptor is known to be an effective strategy for treating cancer and other related diseases. Therefore, in this study, in order to block the inhibitory receptor of TIM-3, we designed and produced recombinantly a protein with a high binding affinity to this receptor.
Methods: The extracellular domain of CEACAM1 involved in binding to TIM-3 was mutated using R script to obtain a variant with the increased binding affinity to TIM-3. The binding energy of the mutant protein was calculated using the FoldX module. Finally, after recombinant production of the most appropriate CEACAM1 variant (variant 39) in E. coli, its secondary structure was determined by CD spectroscopy.
Results: The binding free energy between variant 39 and TIM-3 decreased from -5.63 to -14.49 kcal/mol, indicating an increased binding affinity to the receptor. Analysis of the secondary structure of this variant also showed that the mutation did not significantly alter the structure of the protein.
Conclusion: Our findings suggest that variant 39 could bind to TIM-3 with a higher binding affinity than the wild-type, making it a proper therapeutic candidate for blocking TIM-3.

References
1. Wherry EJ. T cell exhaustion. Nature immunology 2011; 12(6): 492-499. [DOI:10.1038/ni.2035]
2. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nature reviews immunology 2015; 15: 486-499. [DOI:10.1038/nri3862]
3. Su EW, Lin JY, Kane LP. TIM-1 and TIM-3 proteins in immune regulation. Cytokine 2008; 44(1): 9-13. [DOI:10.1016/j.cyto.2008.06.013]
4. Das M, Zhu C, Kuchroo VK. TIM-3 and its role in regulating anti-tumor immunity. Immunological reviews 2017; 276(1): 97-111. [DOI:10.1111/imr.12520]
5. Tang R, Rangachari M, Kuchroo VK. TIM-3: A co-receptor with diverse roles in T cell exhaustion and tolerance. Seminars in immunology 2019; 42: 101302. [DOI:10.1016/j.smim.2019.101302]
6. Kim WM, Huang Y H, Gandhi A, Blumberg RS. CEACAM1 structure and function in immunity and its therapeutic implications. Seminars in immunology 2019; 42: 101296. [DOI:10.1016/j.smim.2019.101296]
7. Terahara K, Yoshida M, Taguchi F, Igarashi O, Nochi T, Gotoh Y, Yamamoto T, Tsunetsugu Yokota Y, Beauchemin N, Kiyono H . Expression of newly identified secretory CEACAM1a isoforms in the intestinal epithelium. Biochemical and biophysical research communications 2009; 383(3): 340-346. [DOI:10.1016/j.bbrc.2009.04.008]
8. Sabatos Peyton CA, Nevin J, Brock A, Venable JD, Tan DJ, Kassam N, Xu F, Taraszka J, Wesemann L, Pertel T, Acharya N, Klapholz M, Etminan Y, Jiang X, Huang YH, Blumberg RS, Kuchroo VK, Anderson C. Blockade of TIM-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-TIM-3 antibodies that have functional efficacy. Oncoimmunology 2018; 7(2): e1385690.. [DOI:10.1080/2162402X.2017.1385690]
9. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, Clayton KL, Raab M, Chen Q, Beauchemin N, Yazaki PJ, Pyzik M, Ostrowski MA, Glickman JN, Rudd CE, Ploegh HL, Franke A, Petsko GA, Kuchroo VK, Blumberg RS. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015; 517(7534): 386-390. [DOI:10.1038/nature13848]
10. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug discovery today 2010; 15(1-2): 40-56. [DOI:10.1016/j.drudis.2009.10.009]
11. Sambrook J. Molecular Cloning: A Laboratory Manual. edition forth. New York: Cold Spring Harbor Laboratory Press, 2012.
12. Lobstein J, Emrich CA, Jeans C, Faulkner M, Riggs P, Berkmen M. SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microbial cell factories 2012; 11(1): 1-16. [DOI:10.1186/1475-2859-11-56]
13. Gholami Tilko P, Hajihassan Z, Moghimi H. Optimization of recombinant β-NGF expression in Escherichia coli using response surface methodology. Preparative biochemistry and biotechnology 2017; 47(4): 406-413. [DOI:10.1080/10826068.2016.1252927]
14. Laemmli U. Cleavage of structure proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685. [DOI:10.1038/227680a0]
15. Armaghan F, Hajihassan Z. Engineering a variant of IL-17RA with high binding affinity to IL-17A for optimized immunotherapy. Biotechnology reports 2021; 32: e00682. [DOI:10.1016/j.btre.2021.e00682]
16. Hajihassan Z, Abdi M, Roshani Yasaghi E, Rabbani Chadegani A. Optimization of recombinant beta-NGF purification using immobilized metal affinity chromatography. Minerva biotecnol 2017; 29: 126-132. [DOI:10.23736/S1120-4826.17.02225-X]
17. Walker JM. The Protein Protocols Handbook. New Jersy: Humana Press Totowa, 2009. [DOI:10.1007/978-1-59745-198-7]
18. Baldo BA. Monoclonal antibodies approved for cancer therapy. Safety of biologics therapy 2016; 13: 57-140. [DOI:10.1007/978-3-319-30472-4_3]
19. Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nature reviews clinical oncology 2016; 13(4): 209-227. [DOI:10.1038/nrclinonc.2015.213]
20. Maute RL,Gordon SR , Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proceedings of the national academy of sciences of the United States of America 2015; 112(47): E6506-E6514. [DOI:10.1073/pnas.1519623112]
21. Hajihassan Z, Afsharian NP, Ansari Pour N. In silico engineering a CD80 variant with increased affinity to CTLA-4 and decreased affinity to CD28 for optimized cancer immunotherapy. Journal of immunological methods 2023; 513: 113425. [DOI:10.1016/j.jim.2023.113425]
22. Fathi Roudsari M, Akhavian Tehrani A, Maghsoudi A. Comparison of three escherichia coli strains in recombinant production of reteplase. Avicenna journal of medical biotechnology 2016; 8(1): 16-22.
23. Zhang C, Freddolino PL, Zhang Y. Improved protein function prediction by combining structure, sequence and protein-protein interaction information. Nucleic acids research 2017; 45(W1): W291-W299. [DOI:10.1093/nar/gkx366]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb